Document:

Exhibit 10.17

 

TRANSITION
SERVICES AGREEMENT

 

This
Transition Services Agreement (the “Transition Services Agreement”) is
made and entered into as of November       , 2006
(the “Effective Date”), by and between Talecris Plasma Resources, Inc.,
a Delaware corporation (“Company”) and International BioResources,
L.L.C., a Louisiana limited liability company (“IBR”).
Company and IBR sometimes are referred to collectively herein as the “Parties” and each individually as a “Party”.
Capitalized terms used and not otherwise defined herein shall have the meanings
ascribed to such terms in the Asset Purchase Agreement (as defined below).

 

WHEREAS,
IBR-BYR L.L.C., a Louisiana limited liability company (the “Seller”), IBR, IBR Plasma Centers, L.L.C., a
Louisiana limited liability company (“IBR PC”), Talecris Biotherapeutics
Holdings Corp., a Delaware corporation (“Holdings”), and Company,
entered into that certain Asset Purchase Agreement dated as of October 31, 2006
(the “Asset Purchase Agreement”),
whereby the parties have agreed to transfer certain assets of the Seller, IBR
and IBR PC to Company (the “Transaction”); and

 

WHEREAS, the plasma collection centers retained by Seller, IBR and IBR PC
(including unlicensed centers and locations under development) (the “Retained
Business”) were not included in the transfer of assets from Seller, IBR and
IBR PC to Buyer as part of the Asset Purchase Agreement; and

 

WHEREAS, IBR and subsidiaries of IBR (collectively, the “IBR Entities”)
will maintain operations of the Retained Business as a stand-alone business;
and

 

WHEREAS, under the terms of the Asset Purchase Agreement, Company is obligated
to provide certain transitional services to the IBR Entities; and

 

WHEREAS, after the Closing, Company will be, among other things, a service
provider with respect to the industry involving the manufacture and
distribution of plasma-derived biological products; and

 

WHEREAS, in order to provide the agreed upon transitional services to the IBR
Entities for operation of the Retained Business, Company has agreed to provide
to the IBR Entities, as part of the Asset Purchase Agreement and for the
additional consideration specified herein, the services described in Section
1.1 and set forth on Exhibit A annexed hereto (the “Services”)
pursuant to the terms and conditions set forth herein, beginning on the date
hereof and continuing for the periods of time set forth herein.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained
herein, the Parties agree, intending to be legally bound, as follows:

 

ARTICLE I

SERVICES

 

1.1           Services.
During the Term (as defined below) applicable to specified Services (as
specified in Section 7.1) Company itself and/or through its employees,
representatives and contractors (collectively, “Representatives”) shall
provide the IBR Entities with the Services as further described on Exhibit A
and in accordance with the terms and conditions of this Transition Services
Agreement. Services shall be provided either on a flat-fee basis or hourly-rate
basis as indicated on Exhibit A; provided, however, that
the cost of Services which Company elects to provide through a third party shall be provided on a pass-though
cost basis and during a Renewal Period (as defined below) shall be subject to a
mark-up consistent with the fee adjustment set forth in Section 3.2. Services
shall in each case be limited to services that Company provides for Company’s
business.

 

1.2           Financial Services. The Parties acknowledge and
agree that with respect to “Financial Services” set forth on Exhibit A
(the “Financial Services”), Company shall be providing support to the
IBR Entities in connection therewith and the IBR Entities will be solely
responsible for the satisfactory completion of the Financial Services and the
reports, products and results attained therefrom.

 

1.3           Training Services. The training Services set forth
on Exhibit A (the “Training Services”) shall be provided on Company
premises and in Company facilities (the “On-Site Training”). Unless
otherwise specified, with respect to On Site Training, IBR personnel shall only
be permitted to observe Company’s performance of the applicable task or service
and shall in no event participate in the execution thereof, provided, however,
that, subject to Company’s approval, not to be unreasonably withheld, IBR
personnel shall be permitted to undertake specified tasks under the 1-to-1
supervision of Company personnel. Each training session shall be scheduled
three (3) weeks in advance of such training session, pursuant to a written request
from the IBR Contract Manager to the Company Contract Manager. The number of
and specific dates for the training sessions will be based on availability of
Company facilities. The Parties shall use reasonable commercial efforts and
cooperate in good faith to schedule such training sessions. Notwithstanding the
foregoing, any training activities of the IBR Entities set forth on Exhibit
B (“Scheduled Training”) in progress as of the Effective Date shall
occur substantially as previously scheduled, and shall be completed within one
(1) week of the projected finish date on Exhibit B. Where the Scheduled
Training has not commenced as of the Effective Date, the Parties shall make
commercially reasonable good faith efforts to adhere to the schedule on Exhibit
B, provided, however, that, in the event that any particular IBR
personnel are not available to engage in and complete such personnel’s
Scheduled Training with one (1) week of the projected finish date, Company
shall have no obligation to complete such Scheduled Training. Scheduled
Training that has not commenced as of the Effective Date shall be provided on a
scope and volume basis proportional to that being done for the Acquired Asset
Entities (as defined in the Asset Purchase Agreement). For the purpose of such
Scheduled Training, “proportional” shall mean the ratio of the total centers
with operating staff retained by IBR relative to those acquired by Company,
whether such centers are licensed, unlicensed or in the process of applying for
a reference number. The IBR Entities shall, and shall ensure that each of its
personnel receiving On-Site Training or other Services at Company facilities
shall, comply with (a) the written policies and procedures that are in effect
with respect to the use and security of Company’s facilities and the protection
and security of Company information; and (b) as applicable, Company’s written
policies and procedures that are in effect during the Term regarding Company’s
business activities, as such procedures are created or modified by Company from
time to time for application to third parties and provided to the IBR Entities.
Any specific modifications to such policy or policies shall be provided by
Company to the IBR Entities. In the event that IBR determines a need for specific
additional Training Services, which Company is able to provide during the Term
with commercially reasonable efforts and without the incurrence of any
additional costs other than the labor required therefore, then Company shall
cooperate in good faith with IBR to provide IBR with such additional Training
Services.

 

1.4           5-D System Training. The Services related to the
Haemonetics Automated Donor Processing System (the “5-D System”) identified as “5-D System
Training” shall consist of: (a) one (1) “Overview Workshop” to be provided at
the Company’s Training Center in Lafayette, Louisiana, acquired pursuant to the
Transaction, and (b) one (1) “Train the Trainer” program designed to enable IBR
trainers to provide function-specific training programs to IBR employees who
will be using the 5-D System in IBR’s plasma collection centers. In addition,
subject to space availability, IBR may enroll up to 5 employees in each
Overview Workshop offered by Company during the relevant Term. IBR may also
enroll up to 3 employees in each Train the Trainer program during the relevant
term, subject to space availability. Attendance at each Overview Workshop
or Train the Trainer program shall
be scheduled thirty (30) days in advance of such training session, pursuant to
a written request from the IBR Contract Manager to the Company Contract Manager.
The number of and specific dates for the training sessions will be based on
availability of the Company facilities. Company will provide a trainer, as
available, to provide reasonable onsite implementation training for IBR
personnel during Talecris 5-D openings. In addition, Company shall provide such
additional 5-D System Training as IBR may reasonably request for the
implementation of the 5-D System in two IBR plasma collection centers, with due
regard for availability of appropriate

 

2

 

Company personnel. The Parties shall use reasonable commercial efforts
and cooperate in good faith to schedule such attendance. Company shall give IBR
reasonable advance notice of available slots for additional “Train the Trainer”
programs and for onsite implementation training and make reasonable efforts to
accommodate IBR training needs.

 

1.5           5-D System Validation. The Services related to the
5-D System identified as “5-D Validation” shall consist of (i) completing the
validation scripts acquired in the Transaction relating to the 5-D System at
Company’s plasma collection centers and providing the output of such scripts to
IBR, (ii) advising IBR on contracting with third parties (including, without
limitation, 5-D/Haemonetics and Focus CVS) to customize configuration elements
of the 5-D System for IBR’s laboratories, test groups, consignees and carriers,
(iii) assisting IBR in developing and executing a validation plan for such
customized configuration elements, (iv) and assisting with the separation of
IBR and Company 5-D Systems, (v) Technical Help Desk and (vi) systems
modification and implementation, provided that in the case of items (v) and (vi)
Company shall not be required to perform custom work suitable only for IBR
application. For the avoidance of doubt, the Services do not include
coordination or providing 5-D system administration and system modification
services except to the extent of sharing materials developed for Company’s 5-D
system administration and system modification. IBR acknowledges and agrees that
IBR shall contract directly with 5-D for such services.

 

1.6           Modification of Services. To the extent that IBR
requires additional transition Services during the Term that are consistent
with the spirit of this Transition Services Agreement, the Parties will
negotiate in good faith for the provision and costs of such Services.

 

1.7           Compensation for Services. The fees attributable to
each Service are set forth in connection with the description of each such
Service on Exhibit A, subject to adjustments for additional direct and
pass-through costs and expenses necessarily incurred by Company in provision of
or support for the Services (e.g.,
Federal Express charges and travel expenses for Company’s Representatives).

 

1.8           Audit. IBR shall have no right to audit Company’s
books and records with respect to the Services provided hereunder or otherwise;
provided, however, that upon IBR’s request, no later than six
months following the termination or expiration of this Transition Services
Agreement, Company shall provide information reasonably necessary to verify the
cost basis upon which fees attributable to the Services provided hereunder have
been calculated.

 

ARTICLE II

SERVICE LEVELS AND PERFORMANCE OBLIGATIONS

 

2.1           Standard of Performance. Company shall provide the
Services with the objective of facilitating the transition of such Services to
the IBR Entities for the ongoing operation of the Retained Business. Each
Service that is the same as or similar to a service provided for the benefit of
or with respect to the Retained Business in the twelve-month period immediately
preceding the Closing, to the extent commercially reasonable, shall be provided
by Company in substantially similar volume, scope, quality and manner to that
with which such service had been performed for the normal ongoing operations of
the Retained Business during such twelve-month period. Specific service levels
for a particular Service may be set forth on Exhibit A hereto. In
connection with its provision of Services, in no event shall Company be
required to (i) make or provide improvements, updates, enhancements or
modifications to the Services, existing systems or technology, even if Company
makes improvements, updates, enhancements or modifications to services provided
internally to Company in each case, except to the extent of the 5-D System
currently being implemented; or (ii) acquire or modify additional systems, technology,
software, assets, rights, properties or other materials or equipment, except to
the extent that Company acquires or modifies systems, technology, software,
assets, rights, properties or other materials or equipment for use in providing
services internally to Company relating to the Haemonetics Automated Donor
Processing System currently being implemented.

 

3

 

2.2           Cooperation. The IBR Entities shall make available
on a timely basis to Company and to its Representatives the IBR Entities’
facilities and information reasonably required or requested by Company to the
extent reasonably necessary to enable Company and its Representatives to
provide the Services. The IBR Entities shall give Company and its Representatives
reasonable access to such facilities and information during normal business
hours and at such other times as are reasonably required and subject to such
reasonable restrictions as the IBR Entities may from time to time prescribe.

 

2.3           No Obligation to Acquire Third Party Licenses. IBR
is responsible for the acquisition of all necessary third party licenses
required to enable and permit Company to provide the Services as contemplated
hereunder. In no event shall Company be responsible for the acquisition of any
such third party licenses. If IBR fails to acquire, renew or otherwise keep in
effect any such third party licenses, Company shall not be obligated to provide
any affected Service until such time as IBR obtains such third party license. For
the avoidance of doubt, any such failure by IBR to obtain any third party
license shall in no event extend the period of time for which Company is
obligated to provide any affected Service.

 

2.4           DISCLAIMER. IBR
ACKNOWLEDGES THAT OTHER THAN AS EXPRESSLY PROVIDED HEREIN, COMPANY
MAKES NO CLAIMS REGARDING THE ACCEPTABILITY, SUITABILITY, AVAILABILITY OR
PERFORMANCE OF THE SERVICES
ANY TRAINING PROVIDED IN CONNECTION THEREWITH; OR ANY SOFTWARE, DATA, PRODUCTS,
PROCESSES, MATERIALS, PROGRAMMING OR OTHER INFORMATION PROVIDED IN CONNECTION
WITH THE SERVICES (COLLECTIVELY, THE “MATERIALS”). ALL SUCH SERVICES,
TRAINING, AND MATERIALS ARE PROVIDED ON AN “AS IS”, “AS AVAILABLE” AND “WITH
ALL FAULTS” BASIS,  AND  WITHOUT WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF TITLE,
MERCHANTABILITY, NON-INFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE. NEITHER
COMPANY NOR ITS OFFICERS, DIRECTORS, REPRESENTATIVES, AGENTS, DEALERS,
SUPPLIERS, PARENTS, SUBSIDIARIES OR AFFILIATES WARRANT THAT THE SERVICES, OR
THE MATERIALS WILL BE SUITABLE, PROVIDED IN A TIMELY MANNER, UNINTERRUPTED,
NON-INFRINGING, ACCURATE, COMPLETE, USEFUL, FUNCTIONAL, SECURE, ERROR FREE OR
FREE OF COMPUTER VIRUSES, WORMS, TROJAN HORSES, OR OTHER MALICIOUS CODE. The disclaimer set forth
in this Section 2.4 shall not be construed to relieve Company from liability
with respect to the matters set forth in the second sentence of Section 5.2.

 

ARTICLE III

PAYMENT

 

3.1           Payment Terms. For each monthly period during the
Term, Company shall submit to IBR an invoice setting forth: (i) the monthly
fees attributable to the Services (in accordance with Exhibit A)
provided to IBR during the preceding calendar month; and (ii) any other direct
or pass-through costs (e.g.,
Federal Express charges or travel expenses for Company’s Representatives) or
other amounts to which Company is entitled to compensation or reimbursement
hereunder attributable to such preceding monthly period. Payment of all amounts
owed by IBR shall be remitted within thirty (30) days from the date of receipt
of the invoice. Any undisputed amounts not paid within such thirty (30) day
period shall be subject to interest (calculated on the basis of the actual days
elapsed from the due date described in the preceding sentence to the date of
actual payment) at a rate of 1.5% per month or the maximum amount permitted by
law, if less. If payment is not made within forty-five (45) days from the date
of receipt of the invoice, Company may offset such amounts against the then
current Milestone Payment and/or Validation Payment due pursuant to the Asset
Purchase Agreement. In the event that IBR, in good faith, disputes the validity
or amount of any charge on such invoice, then IBR shall: (A) promptly provide
Company with written notice of such disputed item, which notice shall
specifically identify the disputed item and explain the reason for such
dispute; and (B) remit when due the undisputed amounts set forth on the invoice.
In the event of any such dispute, Company’s and IBR’s Contract Managers (as
defined below) shall promptly discuss and attempt to resolve the dispute in
good faith. In the event that the Contract Managers are unable to resolve the
dispute within thirty (30) days, the dispute shall be resolved

 

4

 

in accordance with Article 8
hereof. In the event that a dispute is resolved in favor of Company, such
disputed but unremitted amounts shall be subject to interest (calculated on the
basis of the actual days elapsed from the due date described in the preceding
sentence to the date of actual payment) at a rate of 8% per month or the
maximum amount permitted by law, if less. All invoices shall be issued and paid
in U.S. dollars.

 

3.2           Fee Adjustments. In the event that IBR elects to
continue to receive specified Services as described in Section 7.2, the
fees attributable to such specified Services set forth on Exhibit A
shall adjusted by increasing the applicable fees set forth on Exhibit A
by twenty percent (20%) for such additional period.

 

ARTICLE IV

CONFIDENTIALITY

 

4.1           Confidentiality Obligations. All information
provided by one Party to the other Party in connection with this Transition
Services Agreement shall be maintained in strict confidence by the receiving
Party. Such information shall remain the property of the providing Party, and
the receiving Party shall not make use of any such information except for the
purposes for which it was provided. At the termination of this Transition
Services Agreement, upon request, the receiving Party shall promptly return to
the providing Party or destroy any physical embodiments (including copies) of
any such information and provide the providing Party with certification of
destruction.

 

4.2           Exceptions. The covenants of the receiving Party
contained in Section 4.1 shall not apply to information which: (i) is
already in the public domain at the time of disclosure; (ii) becomes part of
the public domain through no action or omission of the receiving Party after
disclosure to the receiving Party; (iii) is already known to the receiving
Party on a non-confidential basis at the time of disclosure, as evidenced by
the receiving Party’s written records, except for information that was known to
Company or its Affiliates prior to the date hereof; (iv) has been or is
disclosed to the receiving Party legally and in good faith by a third party who
was or is not, at the time of disclosure, under any obligation of confidence to
the other Party hereto at the time the third party disclosed such information;
or (v) is required to be disclosed by law, provided that the receiving Party
shall cooperate with the disclosing Party (at the disclosing Party’s expense)
in obtaining any available protection for such information to be disclosed.

 

4.3           Equitable Relief. Each Party acknowledges and
agrees that, in the event of a breach or threatened breach of its
confidentiality obligations above, the other Party will have no adequate remedy
in money damages and, accordingly, shall be entitled to seek injunctive relief
against such breach or threatened breach; provided, however, that
no specification of a particular remedy shall be construed as a waiver,
prohibition or limitation of any other contractual, legal or equitable remedies
in the event of a breach hereof.

 

ARTICLE V

INDEMNIFICATION AND LIMITATION OF LIABILITY

 

5.1           IBR agrees to indemnify, defend and hold harmless Company,
its affiliates, and their respective officers, directors, employees,
representatives and agents against any claim or action based upon or in connection
with any action or claim by a third party arising out of or relating to (a) any
act or omission by any IBR personnel participating in On-Site Training; (b) IBR’s or any IBR personnel’s
performance of the tasks or services for which Company has provided training
under this Transition Services Agreement; or (c) personal or bodily injury or
death or damage to property arising out of IBR’s or its personnel’s performance
hereunder. IBR further agrees to indemnify and hold Company, its
affiliates, and their respective officers, directors, employees,
representatives and agents harmless from and against any and all liabilities,
losses, costs, damages and expenses (including reasonable attorneys’ fees)
associated with any such claim or action. IBR shall have the right to conduct
the defense of any such claim or action and all

 

5

 

negotiations for its settlement
or compromise; provided, however, that (i) that no settlement or compromise
affecting the financial or legal obligations of Company shall be entered into
or agreed to without Company’s prior written approval and (ii) Company has the
right to participate, at its own expense, in the defense and/or settlement of
any such claim or action in order to protect its own interests.

 

5.2           EXCEPT AS OTHERWISE PROVIDED HEREIN, IN NO EVENT SHALL
EITHER PARTY BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL
DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS TRANSITION SERVICES
AGREEMENT, INCLUDING, WITHOUT LIMITATION, LOSS OF ANTICIPATED PROFITS OR
ANTICIPATED REVENUE, AND REGARDLESS OF THE FORM OR CATEGORIZATION OF THE ACTION
OR THE BASIS OF THE CLAIM, WHETHER BASED ON TORT (INCLUDING NEGLIGENCE OR
STRICT LIABILITY) OR BREACH OF CONTRACT CLAIMS OR ON ANY OTHER BASIS, EVEN IF
IT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS SECTION 5.2
SHALL NOT APPLY TO A PARTY’S LIABILITY OR DAMAGES INCURRED WITH RESPECT TO: (i)
IBR’s INDEMNIFICATION OBLIGATIONS SET FORTH HEREIN; (ii) A MATERIAL BREACH OF ARTICLE
4; (iii) THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF EITHER PARTY; (iv)
ANY MISAPPROPRIATION OF COMPANY’S OR ITS LICENSORS’ INTELLECTUAL PROPERTY BY
IBR, ANY IBR AFFILIATE OR ANY IBR ASSIGNEE; OR (v) IBR’S PAYMENT OBLIGATIONS
HEREUNDER.

 

5.3           EXCEPT AS OTHERWISE PROVIDED HEREIN, IN NO EVENT SHALL
EITHER PARTY’S MAXIMUM AGGREGATE LIABILITY TO THE OTHER PARTY ARISING FROM OR
IN CONNECTION WITH THIS TRANSITION SERVICES AGREEMENT EXCEED THE FEES ACTUALLY
PAID BY IBR TO COMPANY HEREUNDER FOR THE TWELVE (12) MONTH PERIOD IMMEDIATELY
PRECEDING THE DATE THAT THE APPLICABLE CLAIM OR ACTION FIRST AROSE, REGARDLESS
OF THE BASIS OF THE CLAIM OR FORM OF ANY ACTION, AND NOTWITHSTANDING THE
FAILURE OF ESSENTIAL PURPOSE OF ANY REMEDY AVAILABLE TO IBR. THIS SECTION
5.3 SHALL NOT APPLY TO A PARTY’S LIABILITY OR DAMAGES INCURRED WITH RESPECT
TO: (i) IBR’s INDEMNIFICATION OBLIGATIONS SET FORTH HEREIN; (ii) A MATERIAL
BREACH OF ARTICLE 4; (iii) THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF
EITHER PARTY; (iv) ANY MISAPPROPRIATION OF COMPANY’S OR ITS LICENSORS’
INTELLECTUAL PROPERTY BY IBR, ANY IBR AFFILIATE OR ANY IBR ASSIGNEE; OR (v)
IBR’S PAYMENT OBLIGATIONS HEREUNDER.

 

ARTICLE VI

RELATIONSHIP

 

6.1           Relationship of Parties. In providing the Services,
Company and each of its Representatives are acting as and shall be considered
independent contractors. Nothing contained herein shall be deemed or construed
by Company, IBR or any other third party as creating the relationship of
employer and employee, principal and agent, partnership, joint employers or
joint venture between the Parties. All Representatives of Company shall be
deemed for all purposes (including compensation and employee benefits) to be
Representatives solely of Company and not to be Representatives of IBR. In
performing their respective duties hereunder, all such Representatives of
Company shall be under the direction, control and supervision of Company (and
not of IBR) and Company shall have the sole right to exercise all authority
with respect to the employment (including termination of employment),
assignment and compensation of such Representatives. Company is not authorized
to, and none of Company’s Representatives shall at any time attempt to (i) act
on behalf of IBR other than as authorized by IBR; or (ii) bind or attempt to
bind IBR in any manner whatsoever. There are no third party beneficiaries,
actual or intended, under this Transition Services Agreement.

 

6

 

6.2          Primary Points of Contact.

 

(a)                                  Appointment and Responsibilities. Each Party shall appoint an individual to
act as the primary point of operational contact for the administration and
operation of this Transition Services Agreement (each, a “Contract Manager”).
The individual appointed by IBR as its Contract Manager (the “IBR Contract
Manager”) will have overall responsibility for: (i) coordinating, on behalf
of IBR, all activities undertaken by IBR hereunder and the performance of the
IBR obligations hereunder; (ii) coordinating the performance of the Services
with Company; (iii) acting as a day-to-day contact with the Company Contract
Manager (as defined below); and (iv) making available to Company the data,
facilities, resources, and other support services from IBR required for Company
to be able to perform the Services in accordance with the terms of this
Transition Services Agreement. The individual appointed by Company as the
primary point of operational contact (the “Company Contract Manager”)
will have overall responsibility for: (1) coordinating, on behalf of Company,
all activities undertaken by Company hereunder and the performance of Company
obligations hereunder; (2) coordinating the performance of the Services with
IBR; (3) acting as a day-to-day contact with the IBR Contract Manager; and (4) providing
IBR with Service performance information and communicating with the IBR
Contract Manager regarding Service requirements and Service management.

 

(b)                                 Review Meetings. The Contract Managers will establish a
schedule of meetings to review Company’s performance of the Services under this
Transition Services Agreement, and to discuss any problems that are unresolved
and any details concerning their expected resolution.

 

6.3          Non-Solicitation/Non-Hire. With
respect to the Company Representatives performing Services under this
Transition Services Agreement, IBR shall abide by the relevant non-solicitation
provisions of the Asset Purchase Agreement.

 

ARTICLE VII

TERM AND TERMINATION

 

7.1          Term. Unless sooner terminated
pursuant to Section 7.3 below, this Transition Services Agreement shall
commence on the Effective Date and shall terminate upon completion of the
Services contemplated herein in accordance with Section 7.2 and the
terms and conditions of this Transition Services Agreement (the “Term”).

 

7.2          Service Periods.

 

(a)                                  Company
shall provide the Services identified as “Quality Validation” on Exhibit A
for a period of 30 days from the Effective Date (the “30-Day Initial Period”);

 

(b)                                 Company
shall provide the Services identified as “Financial Services,” and “Human
Resources” on Exhibit A for a period of 90 days from the Effective Date
(the “90-Day Initial Period”), which 90-Day Initial Period IBR may
extend for an additional period of 90 days (a “Renewal Period”) by
furnishing written notice to Company at least thirty (30) days prior to the end
of the  90-Day Initial Period;

 

(c)                                  Company shall provide the
Services identified as “Training,” “IT Services,” and “Operations/Logistics” on
Exhibit A until the sooner of (i) 180 days from the Effective Date (the
“180-Day Initial Period”) or (ii) the date on which IBR opens its fourth
plasma collection center, which 180-day Initial Period IBR may extend for and
additional 90 

7

 

days
(a “Renewal Period”) by furnishing written notice to Company at least
thirty (30) days prior to the end of the 180-Day Initial Period; and

 

(d)                                 Company
shall provide the Services related to the Haemonetics Automated Donor Processing System (the “5-D System”)
identified
as “5-D System Services” on Exhibit A for a period ending the sooner of
(i) 180 days from the Effective Date (the “180-Day Initial Period”) or
(ii) such time as the modifications
to the standard operating procedures for automated plasma collection centers
(the “Automated SOP”) are validated and implemented in at least one IBR plasma collection center
(the “5-D Period”), which 180-day Initial Period IBR may extend for and
additional 90 days (a “Renewal Period”) by furnishing written notice to
Company at least thirty (30) days prior to the end of the 180-Day Initial
Period.

 

7.3          Termination and Effect of
Termination.

 

(a)                                  Termination by Company. Company may terminate this Transition
Services Agreement, in whole or in part, reserving cumulatively all other
remedies and rights under this Transition Services Agreement and in law and in
equity, if: (i) IBR fails to pay any fees and/or charges not disputed in good
faith within thirty (30) days of the date such fees and/or charges are due and
fails to cure such breach within ten (10) days of receipt of notice from
Company; (ii) IBR materially breaches any provision of this Transition Services
Agreement, other than with respect to IBR’s payment obligations, and fails to
cure such breach within thirty (30) days of receipt of notice from Company;
(iii) IBR becomes bankrupt or insolvent, within the meaning of the United
States Bankruptcy Code or any substantial and relevant portion of its assets
are included in any arrangement with its creditors, an order to wind up or
submission to control by a receiver, assignee or trustee for the purpose of
preserving the assets, whether by the voluntary act of the affected party or
otherwise (but not including submission to control by a liquidating trustee or
agent in connection with a liquidation of IBR initiated by its members in
accordance with its operating agreement as a result of which IBR’s subsidiaries
would continue IBR’s business (a “Special Liquidation”)); or (iv) in the event
IBR undergoes a change of control (other than a Special Liquidation) where
control is acquired, directly or indirectly, in a single transaction or series
of related transactions, or all or substantially all of IBR’s assets are
acquired, by any entity, or IBR is merged with or into another entity to form a
new entity.

 

(b)                                 Termination by IBR. IBR may terminate this Transition Services
Agreement, in whole or in part, reserving cumulatively all other remedies and
rights under this Transition Services Agreement and in law and in equity, if:
(i) Company materially breaches any provision of this Transition Services
Agreement and fails to cure such breach within thirty (30) days of receipt of
notice from IBR; (ii) Company becomes bankrupt or insolvent, within the meaning
of the United States Bankruptcy Code or any substantial and relevant portion of
its assets are included in any arrangement with its creditors, an order to
windup or submission to control by a receiver, assignee or trustee for the
purpose of preserving the assets, whether by the voluntary act of the affected
party or otherwise; or (iii) for convenience upon thirty (30) days written
notice to Company.

 

(c)                                  Effect of Termination. Upon termination of this Transition
Services Agreement, (i) all undisputed outstanding payment obligations of IBR
shall immediately become due and owing; and (ii) IBR shall return to Company
(or destroy at Company’s request) all Company information and materials,
together with all copies thereof, in its possession or under its control,
regardless of the form, format or media on which it is contained and certify in
writing to Company that the same have been returned or destroyed as required
hereunder. For the avoidance of doubt, the business records of Company
regarding the

 

8

 

performance of the Services
hereunder shall remain with Company. If this Transition Services Agreement is
terminated by IBR in whole or in part pursuant to Section 7.2(b)(iii), with
respect to any Service provided on a flat fee basis, IBR shall only be required
to pay the pro rata portion of such flat fee applicable through the date that
termination is effective.

 

ARTICLE VIII

DISPUTE RESOLUTION

 

8.1           The Parties shall attempt in good faith to resolve any
controversy or claim arising out of or relating to this Transition Services Agreement
promptly through negotiations between the Contract Managers or other
representatives and managers of the Parties who have authority to settle the
controversy.

 

8.2           If a controversy or claim should arise, the Contract
Managers will meet at least once within ten (10) days of the date the
controversy arose and will attempt to resolve the matter. The Contract Managers
will make every good faith effort to meet as soon as reasonably possible at a
mutually agreed upon time and place.

 

8.3           If the matter has not been resolved within thirty (30)
days of the meeting of the Contract Managers, then the disputed matter shall be
submitted to and reviewed by an arbitrator (the “Arbitrator”)
selected by the American Arbitration Association (the “AAA”). Such
arbitration shall be conducted by the AAA in New York, New York, under the AAA
Commercial Arbitration Rules as in effect at that time. The Arbitrator shall
consider only the disputed matter(s). The Arbitrator shall act promptly to
resolve all disputed matter(s) and its decision with respect to the disputed
matter(s) shall be final and binding upon the Parties. Upon resolution by the
Arbitrator of all disputed matter(s), the Arbitrator shall cause to be prepared
and shall deliver to the Parties a written decision reflecting the Arbitrator’s
resolution of all disputed matter(s). If the Arbitrator rules against the Party
that originally raised the disputed matter(s), such Party shall be responsible
for the fees and expenses of the arbitration, unless such Arbitrator decides
otherwise.

 

ARTICLE IX

MISCELLANEOUS

 

9.1           Entire Agreement; Amendment; Waiver. This
Transition Services Agreement (including Exhibit A) constitutes the
entire understanding between the Parties with respect to the subject matter
hereof and supersedes all prior agreements and understandings relating to such
subject matter. No provision of this Transition Services Agreement shall be
deemed waived, amended, supplemented or modified by any Party, unless such
waiver, amendment, supplement or modification is in writing and signed by the
authorized representative of the Party against whom it is sought to enforce
such waiver, amendment, supplement or modification. No delay of or omission in
the exercise of any right, power or remedy accruing to either Party as a result
of any breach or default by the other Party under this Transition Services
Agreement shall impair any such right, power or remedy, nor shall it be
construed as a waiver of or acquiescence in any such breach or default, or of
any similar breach or default occurring later; nor shall any waiver of any
single breach or default be deemed a waiver of any other breach or default
occurring before or after that waiver.

 

9.2           Headings. The article, section and paragraph
headings contained in this Transition Services Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of
this Transition Services Agreement.

 

9.3           Counterparts. This Transition Services Agreement
may be executed in counterparts which, taken together, shall constitute the
whole agreement. Executed signatures to this Transition Services

 

9

 

Agreement may be delivered by
any standard electronic means and any such electronically delivered signatures
shall be construed as manually executed signatures.

 

9.4           Severability. In the event that any provision or
requirement of this Transition Services Agreement is in violation of any law or
regulation or otherwise found to be invalid or unenforceable in any jurisdiction:
(a) such provision or requirement shall not be enforced except to the extent it
is not in violation of such laws or regulations or otherwise invalid or
unenforceable; (b) the Parties will promptly renegotiate to restore such
provision or requirement of this Transition Services Agreement as near as
possible to its original interest and effect; and (c) all other provisions and
requirements of this Transition Services Agreement shall remain in full force
and effect.

 

9.5           Publicity. No Party shall issue any press release
or make any public announcement relating to the subject matter of this
Transition Services Agreement without the prior written approval of the other
Party; provided, however, that any Party or its Affiliates may
make any public disclosure it believes in good faith is required by applicable
law or any listing or trading agreement concerning its publicly-traded
securities (in which case the disclosing Party will use commercially reasonable
efforts to advise the other Party prior to making the disclosure).

 

9.6           Set-off. Other than as expressly provided herein,
no Party shall have any right of set-off with respect to the amounts it has an
obligation to pay hereunder.

 

9.6           Notices. All notices and other communications hereunder
shall be in writing (including facsimile or similar writing) and shall be sent,
delivered, mailed, addressed, faxed or e-mailed:if to Company, to:

 

	
   

  	
  Talecris
  Plasma Resources, Inc.

  
	
   

  	
  PO
  Box 110526

  
	
   

  	
  4101
  Research Commons

  
	
   

  	
  79
  T.W. Alexander Drive

  
	
   

  	
  Research
  Triangle Park

  
	
   

  	
  North
  Carolina, USA 27709

  
	
   

  	
  Fax:
  (919) 316-6669

  
	
   

  	
  Attention:
  General Counsel

  
	
   

  	
  E-mail:
  john.gaither@talecris.com

  
	
   

  	
   

  
	
   

  	
  Copy to:

  
	
   

  	
   

  
	
   

  	
  Reed Smith LLP

  
	
   

  	
  599 Lexington Avenue

  
	
   

  	
  29th Floor

  
	
   

  	
  New York, NY 10022

  
	
   

  	
  Fax: (212) 521-5450

  
	
   

  	
  Attention:
  David M. Grimes, Esq.

  
	
   

  	
  E-mail:
  dgrimes@reedsmith.com

  
	
   

  	
   

  
	
   

  	
  if
  to IBR, to:

  
	
   

  	
   

  
	
   

  	
  International BioResources, L.L.C.

  
	
   

  	
  1100 Camellia Boulevard

  
	
   

  	
  Suite 201

  
	
   

  	
  Lafayette, Louisiana 70508

  
	
   

  	
  Fax: (337) 216-6644

  
	
   

  	
  Attention: Rodney L. Savoy

  
	
   

  	
  E-mail: rlsavoy@ibior.com

  

 

10

 

	
   

  	
  Copy
  to:

  
	
   

  	
   

  
	
   

  	
  Fulbright & Jaworski L.L.P.

  
	
   

  	
  666 Fifth Avenue

  
	
   

  	
  New York, New York 10103

  
	
   

  	
  Fax: (212) 318-3400

  
	
   

  	
  Attention: Neil Gold, Esq.

  
	
   

  	
  E-mail: ngold@fulbright.com

  

 

or such other address,
facsimile number or e-mail address as such Party may hereafter specify for the
purpose of notice to the other Party hereto. Each such notice or other
communication shall be given (i) by hand delivery; (ii) by nationally
recognized courier service; (iii) by facsimile, receipt confirmed; or (iv) by
e-mail, receipt confirmed. Each such notice or communication shall be effective
(A) if delivered by hand or by nationally recognized courier service, when
delivered at the address specified in this Section 9.7 (or in accordance
with the latest unrevoked direction from such Party); (B) if given by
facsimile, when such facsimile is transmitted to the facsimile number specified
in this Section 9.7 (or in accordance with the latest unrevoked
direction from such Party), and confirmation is received; and (C) if given by
e-mail, when such e-mail is transmitted to the e-mail address specified in this
Section 9.7 (or in accordance with the last unrevoked direction from
such Party), and confirmation (by return receipt or reply by the recipient) is
received.

 

9.8           Governing Law, Jurisdiction and Venue. This
Transition Services Agreement shall be governed by and construed in accordance
with the laws of the State of New York applicable to contracts made and to be
wholly performed therein, without giving effect to the principles of conflicts
of law thereof. Any action or proceeding seeking to enforce any provision of,
or based on any right arising out of, this Transition Services Agreement may be
brought against any of the Parties in the courts of the State of New York,
County of New York, or, if it has or can acquire jurisdiction, in the United
States District Court for the Southern District of New York, and each of the
Parties consents to the jurisdiction of such courts (and of the appropriate
appellate courts) in any such action or proceeding and waives any objection to
venue laid therein. Process in any action or proceeding referred to in the
preceding sentence may be served on any Party anywhere in the world.

 

9.9           Assignment. This Transition Services Agreement and
all of the provisions hereof shall be binding upon and inure to the benefit of
the Parties hereto and their respective successors and assigns, and it is not
intended to confer upon any other third party any rights or remedies hereunder.
Neither this Transition Services Agreement nor any of the rights, interests or
obligations hereunder may be assigned by any of the Parties without the prior
written consent of the other Party hereto, except that each Party may at any
time assign any or all of its rights or obligations hereunder to one of its
wholly owned subsidiaries (but no such assignment shall relieve such Party of
any of its obligations under this Transition Services Agreement). Either Party
may assign this License Agreement and any or all rights or obligations
hereunder to (i) any Affiliate of such Party; provided that any such
Affiliate becomes a party to this License Agreement or (ii) any successor in
interest to such Party; provided that any such successor becomes a party
to this License Agreement; provided that no assignment under (i) or (ii) above
shall relieve either Party from any obligations hereunder, and in the case of
(i) and (ii), such assignee has qualifications and capabilities needed to
perform such Party’s or its Affiliates’ obligations hereunder. Any purported
assignment in contravention of this Section 9.9 shall be void ab initio and of no force and effect.

 

9.10         Force Majeure. Neither Party will be in default of
its obligations to the extent its performance is delayed or prevented by causes
beyond its control, including but not limited to acts of God, earthquake,
flood, embargo, riots, sabotage, utility or transmission failures, fire, labor
disturbances, acts of war, acts of terror, radiological, nuclear, chemical, or
biological attack, or spread of infectious disease. Neither Party nor its
representatives will be liable for loss or damage or deemed to be in breach of
this Transition Services Agreement if its failure to perform its obligations
results from compliance with any law, ruling, order, regulation, requirement of
any federal, state or municipal government or department or agency thereof or
court of competent jurisdiction.

 

11

 

9.11         Construction. The Parties have participated jointly
in the negotiation and drafting of this Transition Services Agreement. In the
event an ambiguity or question of intent or interpretation arises, this
Transition Services Agreement shall be construed as if drafted jointly by the
Parties and no presumption or burden of proof shall arise favoring or
disfavoring any Party by virtue of the authorship of any of the provisions of
this Transition Services Agreement. Any reference to any federal, state, local,
or foreign statute or law shall be deemed also to refer to all rules and
regulations promulgated thereunder, unless the context requires otherwise. The
word “including” shall mean including without limitation.

 

9.12         Survival. Any provision of this Transition Services
Agreement that by its nature must survive expiration or termination of this
Transition Services Agreement to give such provision its meaning shall survive
such expiration or termination.

 

[SIGNATURE PAGE FOLLOWS]

 

12

 

IN WITNESS WHEREOF, the Parties have caused this Transition Services Agreement to be
signed by their respective officers thereunto duly authorized, all as of the
date first written above.

 

	
   

  	
  TALECRIS PLASMA RESOURCES, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ RANDALL A. JONES

  
	
   

  	
  Name:

  	
  Randall A. Jones

  
	
   

  	
  Title:

  	
  Vice President

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  INTERNATIONAL BIORESOURCES, L.L.C.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ RODNEY L. SAVOY

  
	
   

  	
  Name:

  	
  Rodney L. Savoy

  
	
   

  	
  Title:

  	
  CEOExhibit 10.18

 

LICENSE
AGREEMENT

 

This
License Agreement (the “License Agreement”) is made and entered into as
of November     , 2006 (the “Effective Date”), by
and between Talecris Plasma Resources, Inc., a Delaware corporation (“Company”)
and International BioResources, L.L.C., a Louisiana limited liability company (“IBR”).
Company and IBR sometimes are referred to collectively herein as the “Parties” and each individually as a “Party”.
Capitalized terms used and not otherwise defined herein shall have the meanings
ascribed to such terms in the Asset Purchase Agreement (as defined below).

 

WHEREAS, IBR-BYR L.L.C., a Louisiana limited
liability company (the “Seller”), IBR, IBR
PlasmaCenters, L.L.C., a Louisiana limited liability company, Talecris
Biotherapeutics Holdings Corp., a Delaware corporation (“Holdings”), and
the Company, entered into that certain Asset Purchase Agreement dated as of
October 31, 2006 (the “Asset Purchase Agreement”), whereby certain assets of
Seller, including the Licensed Materials (as defined below) in existence as of
the date hereof, were transferred to the Company; and

 

WHEREAS, IBR, directly and through its subsidiaries
(collectively, the “IBR Entities”) will continue to operate its other
plasma centers (the “Retained Centers”) and intends to open additional
plasma centers for its existing customers and for new customers in the source
plasma, specialty plasma and other related businesses (references herein to IBR’s
rights under the license granted herein shall include IBR and the other IBR
Entities); and

 

WHEREAS, Company has agreed to grant IBR the right
to use all intellectual property used by IBR in the operation of the Retained
Centers prior to Closing (as defined in the Asset Purchase Agreement),
including but not limited to the standard operating procedures for the
operation of plasma collection centers (“SOP”) and manuals, included
within the Acquired Assets (as defined in the Asset Purchase Agreement) and set
forth on Exhibit A, as well as the right to certain modifications to the
SOP for automated plasma collection centers (the “Automated SOP”)
(collectively, the “Licensed Materials”), pursuant to the terms and
conditions set forth herein.

 

NOW,
THEREFORE, in
consideration of the mutual covenants and agreements contained herein, the
Parties agree, intending to be legally bound, as follows:

 

ARTICLE I

GRANT OF LICENSE

 

1.1           License. Subject to the terms and conditions of
this Agreement, to the extent, and only to the extent, that Company possesses
rights in the Licensed Materials, Company hereby grants to IBR a perpetual,
irrevocable, non-exclusive, royalty-free, transferable (pursuant to Section
6.8), sublicensable (pursuant to Section 6.8) license to use the Licensed
Materials in existence as of the Closing, and any changes and modifications
made by Company to the Automated SOP made subsequent to Closing and prior to
the date of the first validation of an IBR plasma collection center, in the
operation of the Retained Centers and additional plasma centers for its
existing customers and for new customers in the source plasma, specialty plasma
and other related businesses.

 

1.2           Additional Centers. For the sake of clarity, it is
specifically agreed that IBR may use the Licensed Materials in existing plasma
collection centers owned by IBR and in additional plasma collection centers
that IBR may own in the future and to collect plasma (including specialty
plasma) for all current and future customers in plasma collection centers owned
by IBR without restriction of any kind, except as expressly set forth herein.

 

1.3           Copying and Modification. IBR may make one or more
copies, in whole or in part, of the Licensed Materials and may modify, adapt,
translate, and create derivative works based on the Licensed

 

 

Materials. As set forth in Section
6.8, IBR may sell, sublicense, transfer or distribute the Licensed Materials
solely in connection with the sale of an IBR plasma collection center.

 

1.4           Ownership. Except as otherwise provided herein,
Company shall retain all rights and ownership with respect to the Licensed
Materials.

 

ARTICLE II

DISCLAIMER AND LIMITATION OF LIABILITY

 

2.1           DISCLAIMER. IBR
ACKNOWLEDGES THAT COMPANY MAKES NO CLAIMS REGARDING THE
ACCEPTABILITY, SUITABILITY, AVAILABILITY OR PERFORMANCE OF THE LICENSED MATERIALS. ALL SUCH
LICENSED MATERIALS ARE PROVIDED ON AN “AS IS”, “AS AVAILABLE” AND “WITH ALL
FAULTS” BASIS,  AND  WITHOUT WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF TITLE,
MERCHANTABILITY, NON-INFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE. IN
NO EVENT SHALL COMPANY BE REQUIRED TO UPDATE, MODIFY, ENHANCE OR OTHERWISE
PROVIDE ANY OTHER ADDITIONAL INFORMATION WITH RESPECT TO THE LICENSED MATERIALS
EXCEPT AS SPECIFICALLY AGREED WITH RESPECT TO THE AUTOMATED SOP. NEITHER COMPANY NOR ITS
OFFICERS, DIRECTORS, REPRESENTATIVES, AGENTS, DEALERS, SUPPLIERS, PARENTS,
SUBSIDIARIES OR AFFILIATES WARRANT THAT THE LICENSED MATERIALS WILL BE
SUITABLE, NON-INFRINGING, ACCURATE, COMPLETE, CONSISTENT WITH INDUSTRY PRACTICE
OR STANDARDS, USEFUL, FUNCTIONAL, SECURE, ERROR-FREE OR IN COMPLIANCE WITH ANY
LAW, RULE, REGULATION OR STANDARDS OF ANY GOVERNMENTAL BODY, INCLUDING, WITHOUT
LIMITATION, THOSE OF THE FDA.

 

2.2           LIMITATION
OF LIABILITY. IN NO EVENT SHALL COMPANY BE LIABLE FOR ANY INDIRECT, INCIDENTAL,
SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS
AGREEMENT, INCLUDING, WITHOUT LIMITATION, LOSS OF ANTICIPATED PROFITS OR
ANTICIPATED REVENUE, AND REGARDLESS OF THE FORM OR CATEGORIZATION OF THE ACTION
OR THE BASIS OF THE CLAIM, WHETHER BASED ON TORT (INCLUDING NEGLIGENCE OR
STRICT LIABILITY) OR BREACH OF CONTRACT CLAIMS OR ON ANY OTHER BASIS, EVEN IF
IT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL
COMPANY’S MAXIMUM AGGREGATE LIABILITY TO THE OTHER PARTY ARISING FROM OR IN
CONNECTION WITH THIS AGREEMENT EXCEED ONE THOUSAND DOLLARS ($1,000), REGARDLESS
OF THE BASIS OF THE CLAIM OR FORM OF ANY ACTION, AND NOTWITHSTANDING THE
FAILURE OF ESSENTIAL PURPOSE OF ANY REMEDY AVAILABLE TO IBR.

 

ARTICLE III

CONFIDENTIALITY

 

3.1           Confidentiality Obligations. For a period of four
years from Closing, the Licensed Materials shall be maintained in confidence by
IBR in the same manner and to the same degree that IBR historically has used
with respect to the Licensed Materials. Such Licensed Materials shall remain
the property of the Company, and IBR shall not make use of any such Licensed
Materials except for the purposes for which it was provided. At the termination
of this License Agreement, upon request, IBR shall promptly return to Company
or destroy any physical embodiments (including copies) of any such Licensed
Materials and provide the Company with certification of destruction. Notwithstanding
the foregoing, where necessary, IBR may provide any of the Licensed Materials
to a customer or potential customer who may reasonably request that
information.

 

3.2           Exceptions. The covenants of IBR contained in
Section 3.1 shall not apply after a period of four years from Closing or to
information which: (i) is already in the public domain at the time of
disclosure;

 

2

 

(ii) becomes part of the public
domain through no action or omission of either Party after disclosure to IBR;
(iii) is already known to IBR on a non-confidential basis at the time of
disclosure, as evidenced by IBR’s written records; (iv) is already known to IBR
prior to the date hereof; (v) has been or is disclosed to IBR legally and in
good faith by a third party who was or is not, at the time of disclosure, under
any obligation of confidence to the Company at the time the third party
disclosed such information; or (vi) is required to be disclosed by law,
provided that IBR shall cooperate with the Company (at the Company’s expense)
in obtaining any available protection for such information to be disclosed.

 

3.3           Equitable Relief. IBR acknowledges and agrees that,
in the event of a breach or threatened breach of its confidentiality
obligations above, the Company will have no adequate remedy in money damages and,
accordingly, shall be entitled to seek injunctive relief against such breach or
threatened breach; provided, however, that no specification of a particular
remedy shall be construed as a waiver, prohibition or limitation of any other
contractual, legal or equitable remedies in the event of a breach hereof.

 

ARTICLE IV

TERM AND TERMINATION

 

4.1           Term. This License Agreement shall commence on the
Effective Date and shall continue in perpetuity.

 

ARTICLE V

DISPUTE RESOLUTION

 

5.1           The Parties shall attempt in good faith to resolve any
controversy or claim arising out or relating to this License Agreement promptly
through negotiations between the representatives and managers of the Parties
(the “Representatives”) who have authority to settle the controversy.

 

5.2           If a controversy or claim should arise, the
Representatives will meet at least once within ten (10) days of the date the
controversy arose and will attempt to resolve the matter. The Representatives
will make every good faith effort to meet as soon as reasonably possible at a
mutually agreed upon time and place.

 

5.3           If the matter has not been resolved within thirty (30)
days of the meeting of the Representatives, then the disputed matter shall be
submitted to and reviewed by an arbitrator (the “Arbitrator”)
selected by the American Arbitration Association (the “AAA”). Such
arbitration shall be conducted by the AAA in New York, New York, under the AAA
Commercial Arbitration Rules as in effect from time to time.  The
Arbitrator shall consider only the disputed matter(s).  The Arbitrator
shall act promptly to resolve all disputed matter(s) and its decision with
respect to the disputed matter(s) shall be final and binding upon the Parties.
Upon resolution by the Arbitrator of all disputed matter(s), the Arbitrator
shall cause to be prepared and shall deliver to the Parties a written decision
reflecting the Arbitrator’s resolution of all disputed matter(s). If the
Arbitrator rules against the Party that originally raised the disputed
matter(s), such Party shall be responsible for the fees and expenses of the
arbitration, unless such Arbitrator decides otherwise.

 

5.4           If Company believes in good faith that IBR has materially
breached Article 3 or Section 6.8 of this License Agreement, then Company may
give IBR written notice of such breach, which notice shall specifically
identify the alleged breach and specifically set forth a proposed cure or cures
for such breach. Within ten (10) days of receipt of such notice from Company,
IBR shall provide written notice to Company (i) contesting Company’s claim that
IBR is in material breach, (ii) contesting Company’s proposed cure for such
breach and proposing its own cure; or (iii) that IBR has or will cure the
breach in the manner proposed in Company’s notice within thirty (30) days of
furnishing such written notice to Company. Where IBR contests the proposed
cure(s) for the breach and proposes its own cure(s),

 

3

 

Company shall provide written
notice to IBR within ten (10) days of receipt of IBR’s notice accepting or
rejecting IBR’s proposed cure. If Company accepts IBR’s cure, IBR shall cure
the breach in the manner proposed by IBR within thirty (30) days of receipt of
such Company notice. Where IBR contests the existence of the breach, where
Company rejects IBR’s proposed cure(s) for the breach, or where IBR has
asserted that it has cured the breach but Company contests the adequacy or
timeliness of that cure, Company and IBR shall resolve such dispute pursuant to
this Article V. The Arbitrator’s remedies shall not include termination of this
License Agreement, and damages shall be calculated for the first three years
from the Effective Date as the greater of (a) actual damages or (b) liquidated
damages equal to the lesser of (Y) two dollars ($2) per liter of plasma
collected by IBR during the period in which IBR is in breach or (Z) $200,000; provided,
however, that such liquidated damages shall cease to be a remedy after a
period of three years from the Effective Date. The Arbitrator’s decision shall
be final and binding upon the Parties.

 

ARTICLE VI

MISCELLANEOUS

 

6.1           Entire Agreement; Amendment; Waiver. This License
Agreement (including Exhibit A) constitutes the entire understanding
between the Parties with respect to the subject matter hereof and supersedes
all prior agreements and understandings relating to such subject matter. No
provision of this License Agreement shall be deemed waived, amended,
supplemented or modified by any Party, unless such waiver, amendment, supplement
or modification is in writing and signed by the authorized representative of
the Party against whom it is sought to enforce such waiver, amendment,
supplement or modification. No delay of or omission in the exercise of any
right, power or remedy accruing to either Party as a result of any breach or
default by the other Party under this License Agreement shall impair any such
right, power or remedy, nor shall it be construed as a waiver of or
acquiescence in any such breach or default, or of any similar breach or default
occurring later; nor shall any waiver of any single breach or default be deemed
a waiver of any other breach or default occurring before or after that waiver.

 

6.2           Headings. The article, section and paragraph
headings contained in this License Agreement are for reference purposes only
and shall not affect in any way the meaning or interpretation of this License
Agreement.

 

6.3           Counterparts. This License Agreement may be
executed in counterparts which, taken together, shall constitute the whole
agreement. Executed signatures to this License Agreement may be delivered by
any standard electronic means and any such electronically delivered signatures
shall be construed as manually executed signatures.

 

6.4           Severability. In the event that any provision or
requirement of this License Agreement is in violation of any law or regulation
or otherwise found to be invalid or unenforceable in any jurisdiction: (a) such
provision or requirement shall not be enforced except to the extent it is not
in violation of such laws or regulations or otherwise invalid or unenforceable;
(b) the Parties will promptly renegotiate to restore such provision or
requirement of this License Agreement as near as possible to its original
interest and effect; and (c) all other provisions and requirements of this
License Agreement shall remain in full force and effect.

 

6.5           Relationship of Parties; No Third Party Beneficiaries. Nothing
contained herein shall be deemed or construed by Company, IBR or any other
third party as creating the relationship of employer and employee, principal
and agent, partnership, joint employers or joint venture between the Parties. This
License Agreement shall not confer any rights or remedies upon any third party
other than the Parties and their respective successors and permitted assigns.

 

4

 

6.6           Notices. All notices and other communications
hereunder shall be in writing (including facsimile or similar writing) and
shall be sent, delivered, mailed, addressed, faxed or e-mailed:

 

	
   

  	
  if
  to Company, to:

  
	
   

  	
   

  
	
   

  	
  Talecris
  Plasma Resources, Inc.

  
	
   

  	
  PO
  Box 110526

  
	
   

  	
  4101
  Research Commons

  
	
   

  	
  79
  T.W. Alexander Drive

  
	
   

  	
  Research
  Triangle Park

  
	
   

  	
  North
  Carolina, USA 27709

  
	
   

  	
  Fax:
  (919) 316-6669

  
	
   

  	
  Attention:
  General Counsel

  
	
   

  	
  E-mail:
  john.gaither@talecris.com

  
	
   

  	
   

  
	
   

  	
  Copy to:

  
	
   

  	
   

  
	
   

  	
  Reed Smith LLP

  
	
   

  	
  599 Lexington Avenue

  
	
   

  	
  29th Floor

  
	
   

  	
  New York, NY 10022

  
	
   

  	
  Fax: (212) 521-5450

  
	
   

  	
  Attention:
  David M. Grimes, Esq.

  
	
   

  	
  E-mail:
  dgrimes@reedsmith.com

  
	
   

  	
   

  
	
   

  	
  if
  to IBR, to:

  
	
   

  	
   

  
	
   

  	
  International BioResources, L.L.C.

  
	
   

  	
  1100 Camellia Boulevard

  
	
   

  	
  Suite 201

  
	
   

  	
  Lafayette, Louisiana 70508

  
	
   

  	
  Fax: (337) 216-6644

  
	
   

  	
  Attention: Rodney L. Savoy

  
	
   

  	
  E-mail: rlsavoy@ibior.com

  
	
   

  	
   

  
	
   

  	
  Copy to:

  
	
   

  	
   

  
	
   

  	
  Fulbright & Jaworski L.L.P.

  
	
   

  	
  666 Fifth Avenue

  
	
   

  	
  New York, New York 10103

  
	
   

  	
  Fax: (212) 318-3400

  
	
   

  	
  Attention: Neil Gold, Esq.

  
	
   

  	
  E-mail: ngold@fulbright.com

  

 

or to such other address,
facsimile number or e-mail address as such Party may hereafter specify for the
purpose of notice to the other Party hereto. Each such notice or other
communication shall be given (i) by hand delivery; (ii) by nationally
recognized courier service; (iii) by facsimile, receipt confirmed; or (iv) by
e-mail, receipt confirmed. Each such notice or communication shall be effective
(A) if delivered by hand or by nationally recognized courier service, when
delivered at the address specified in this Section 6.6 (or in accordance with
the latest unrevoked direction from such Party); (B) if given by facsimile,
when such facsimile is transmitted to the facsimile number specified in this
Section 6.6 (or in accordance with the latest unrevoked direction from such
Party), and confirmation is received; and (C) if given by e-mail, when such
e-mail is transmitted to the e-mail address specified in this Section 5.6 (or
in accordance with the last unrevoked direction from such Party), and
confirmation (by return receipt or reply by the recipient) is received.

 

5

 

6.7           Governing Law,
Jurisdiction and Venue. This License Agreement shall be governed by and
construed in accordance with the laws of the State of New York applicable to
contracts made and to be wholly performed therein, without giving effect to the
principles of conflicts of law thereof. Any action or proceeding seeking to
enforce any provision of, or based on any right arising out of, this License
Agreement may be brought against any of the Parties in the courts of the State
of New York, County of New York, or, if it has or can acquire jurisdiction, in
the United States District Court for the Southern District of New York, and
each of the Parties consents to the jurisdiction of such courts (and of the
appropriate appellate courts) in any such action or proceeding and waives any
objection to venue laid therein. Process in any action or proceeding referred
to in the preceding sentence may be served on any Party anywhere in the world.

 

6.8           Assignment and
Sublicense. This License Agreement and all of the provisions hereof shall
be binding upon and inure to the benefit of the Parties hereto and their
respective successors and assigns, and it is not intended to confer upon any
other third party any rights or remedies hereunder. For a period of four years
from Closing, neither this License Agreement nor any of the rights, interests
or obligations hereunder may be assigned or sublicensed by any of the Parties
without the prior written consent of the other Party hereto, except that each
Party may at any time assign or sublicense any or all of its rights or
obligations hereunder to one of its wholly owned subsidiaries (but no such
assignment shall relieve such Party of any of its obligations under this
License Agreement). Either Party may assign this License Agreement and any or
all rights or obligations hereunder to (i) any Affiliate of such Party; provided
that any such Affiliate becomes a party to this License Agreement or (ii) any
successor in interest to such Party; provided that any such successor
becomes a party to this License Agreement; provided that no assignment under
(i) or (ii) above shall relieve either Party from any obligations hereunder,
and in the case of (i) and (ii), such assignee has qualifications and
capabilities needed to perform such Party’s or its Affiliates’ obligations
hereunder. After such four year period, IBR may assign or sublicense its rights
under this License Agreement without restriction. Any purported assignment in
contravention of this Section 6.8 shall be void ab initio
and of no force and effect.

 

6.9           Force Majeure.
Neither Party will be in default of its obligations to the extent its
performance is delayed or prevented by causes beyond its control, including but
not limited to acts of God, earthquake, flood, embargo, riots, sabotage,
utility or transmission failures, fire, labor disturbances, acts of war, acts
of terror, radiological, nuclear, chemical, or biological attack, or spread of
infectious disease. Neither Party nor its representatives will be liable for
loss or damage or deemed to be in breach of this License Agreement if its
failure to perform its obligations results from compliance with any law,
ruling, order, regulation, requirement of any federal, state or municipal
government or department or agency thereof or court of competent jurisdiction.

 

6.10         Construction. The
Parties have participated jointly in the negotiation and drafting of this
License Agreement. In the event an ambiguity or question of intent or
interpretation arises, this License Agreement shall be construed as if drafted
jointly by the Parties and no presumption or burden of proof shall arise
favoring or disfavoring any Party by virtue of the authorship of any of the
provisions of this License Agreement. Any reference to any federal, state,
local, or foreign statute or law shall be deemed also to refer to all rules and
regulations promulgated thereunder, unless the context requires otherwise. The
word “including” shall mean including without limitation.

 

6.11         Survival. Any
provision of this License Agreement that by its nature must survive termination
of this License Agreement to give such provision its meaning shall survive such
termination.

 

[SIGNATURE PAGE FOLLOWS]

 

6

 

IN
WITNESS WHEREOF, the
Parties have caused this License Agreement to be signed by their respective
officers thereunto duly authorized, all as of the date first written above.

 

	
   

  	
  TALECRIS PLASMA RESOURCES, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ RANDALL A. JONES

  	
   

  
	
   

  	
  Name:

  	
   Randall A.
  Jones

  	
   

  
	
   

  	
  Title:

  	
  Vice President

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  INTERNATIONAL BIORESOURCES, L.L.C.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ RODNEY L. SAVOY

  	
   

  
	
   

  	
  Name:

  	
   Rodney L.
  Savoy

  	
   

  
	
   

  	
  Title:

  	
  CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]